Lista de obras -

An ider(17)(q10)t(15;17) with spliced long-type PML-RARA fusion transcripts in a case of acute promyelocytic leukemia.

artículo científico publicado en 2014

Antitumor activity of fucoidan against diffuse large B cell lymphoma in vitro and in vivo.

artículo científico publicado en 2015

Antitumor effect of dobutamine on multiple myeloma via mitogen-activated protein kinase pathway in vitro.

artículo científico publicado en 2016

Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2 ⬇️

artículo científico publicado el 1 de diciembre de 2010

Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cells

scientific article published on 08 March 2011

Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma

artículo científico publicado en 2015

Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy

artículo científico publicado en 2018

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.

artículo científico publicado en 2015

DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.

artículo científico publicado en 2017

Differential regulation of prostaglandin production mediated by corticotropin-releasing hormone receptor type 1 and type 2 in cultured human placental trophoblasts.

artículo científico publicado en 2008

Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo.

artículo científico publicado en 2017

Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trials

artículo científico publicado en 2014

Inferior prognosis of gastric involvement in patients with gastrointestinal Burkitt Lymphoma

artículo científico publicado en 2020

Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials

artículo científico publicado en 2014

Myeloma bone disease: Progress in pathogenesis

artículo científico publicado en 2016

Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism.

artículo científico publicado en 2014

Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.

artículo científico publicado en 2016

Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma

artículo científico publicado en 2017

Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.

artículo científico publicado en 2014

Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo.

artículo científico publicado en 2016

Pterostilbene induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma cells.

artículo científico publicado en 2016

Regulation of estradiol and progesterone production by CRH-R1 and -R2 is through divergent signaling pathways in cultured human placental trophoblasts

artículo científico publicado en 2012

Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials

artículo científico publicado en 2015

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2.

artículo científico publicado en 2015

TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma

artículo científico publicado en 2017

Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.

artículo científico publicado en 2016

The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells

artículo científico publicado en 2017

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma

scientific article published on 09 April 2016

Lista de obras de

An ider(17)(q10)t(15;17) with spliced long-type PML-RARA fusion transcripts in a case of acute promyelocytic leukemia.

Antitumor activity of fucoidan against diffuse large B cell lymphoma in vitro and in vivo.

Antitumor effect of dobutamine on multiple myeloma via mitogen-activated protein kinase pathway in vitro.

Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2 ⬇️

Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cells

Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma

Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.

DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.

Differential regulation of prostaglandin production mediated by corticotropin-releasing hormone receptor type 1 and type 2 in cultured human placental trophoblasts.

Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo.

Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trials

Inferior prognosis of gastric involvement in patients with gastrointestinal Burkitt Lymphoma

Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials

Myeloma bone disease: Progress in pathogenesis

Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism.

Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.

Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma

Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.

Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo.

Pterostilbene induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma cells.

Regulation of estradiol and progesterone production by CRH-R1 and -R2 is through divergent signaling pathways in cultured human placental trophoblasts

Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2.

TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma

Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.

The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma